Biodexa Pharmaceuticals (BDRX) Cash from Operations (2013 - 2021)
Biodexa Pharmaceuticals (BDRX) reported Cash from Operations of 4318519.09 for Q3 2021, up 51.62% on a YoY basis from 2848299.4 in Q3 2020, and up 53.86% sequentially from 9359356.7 in Q4 2020.
Biodexa Pharmaceuticals (BDRX) Cash from Operations (2013 - 2021) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 7 years of Cash from Operations data on file, last reported at 4318519.09 in Q3 2021.
- For the quarter ending Q3 2021, Cash from Operations rose 51.62% year-over-year to 4318519.09; the trailing twelve-month figure through Sep 2021 stood at 28467846.31 (up 42.96% YoY), and the FY2025 full-year result was 7371791.29, up 53.16% from the prior year.
- Cash from Operations rose to 4318519.09 in Q3 2021, from 9359356.7 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 4318519.09 in Q3 2021 to a low of 9359356.7 in Q4 2020.
- A 3-year average of 7116961.58 and a median of 7394985.26 in 2019 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations slumped 59.6% in 2020 and soared 51.62% in 2021, its largest moves.
- Tracing BDRX's Cash from Operations over 3 years: stood at 5864191.29 in 2019, then tumbled by 59.6% to 9359356.7 in 2020, then jumped by 53.86% to 4318519.09 in 2021.
- Business Quant data shows BDRX's Cash from Operations at 4318519.09 in Q3 2021, 9359356.7 in Q4 2020, and 8925779.23 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 17, 2021 | -4.32 Mn |
| Sep 17, 2021 | -4.32 Mn |
| Dec 31, 2020 | -9.36 Mn |
| Dec 31, 2020 | -9.36 Mn |
| Sep 10, 2020 | -8.93 Mn |
| Sep 10, 2020 | -8.93 Mn |
| Dec 31, 2019 | -5.86 Mn |
| Dec 31, 2019 | -5.86 Mn |
| Dec 31, 2016 | -16.27 Mn |
| Dec 31, 2016 | -16.27 Mn |
| Dec 31, 2015 | -18.85 Mn |
| Dec 31, 2015 | -18.85 Mn |
| Dec 31, 2014 | -8.64 Mn |
| Dec 31, 2014 | -8.64 Mn |
| Dec 31, 2013 | -7.18 Mn |
| Dec 31, 2013 | -7.18 Mn |